The SenoReverse™ skin product line returns dermal fibroblasts to a younger biological age, so that the dermis rebuilds its own structure and the surface follows. The product line is registered, and its efficacy has been substantiated in instrument-graded human studies conducted by an independent third-party laboratory.
Fortnightly cohort, treated side vs baseline; untreated side of the same face +4.63%.
Fortnightly cohort, treated side vs baseline; untreated side −1.23%.
Two independent cohorts, 84 completers, full course.
With age, dermal fibroblasts enter cell-cycle arrest: they enlarge, flatten, cease synthesizing new collagen, and release inflammatory signals that arrest neighboring cells in turn. Collagen loss, dermal thinning, and surface folding appear years later as consequences of that event.
SenoReverse™ returns arrested fibroblasts to a younger biological age. The arrest is released, the cells return to a young functional state, and they synthesize type-I collagen and elastin again. A younger face is the outcome of that chain, not the target of it.
Unlike the prevailing approaches in medical aesthetics, the product line produces no fibrosis, no overfilled appearance, and does not borrow against the skin's future: the biological age of the cells is genuinely reduced, and the appearance follows from that.
The nucleic acid enters senescent cells and not healthy ones. Once delivery is complete it is metabolized and cleared, and no material remains.
The cell body respreads and re-attaches to its fiber network, and its capacity for proliferation and synthesis returns to youthful levels.
New type-I collagen self-assembles along the existing scaffold into a woven network, structurally identical to that of young skin rather than the parallel bundles of repair collagen.
The dermal–epidermal junction regains its undulation and matrix volume is restored; wrinkles and contours improve as the structure beneath them is rebuilt.
The mechanism predicts the order in which instruments should register change: elasticity first, as the cells resume function, and wrinkle metrics later, as the matrix rebuilds.
Two independent cohorts were studied: 86 subjects enrolled and 84 completed, aged 37 to 60, all presenting moderate-to-severe wrinkles across five zones together with laxity. Baseline severity was near-identical between the cohorts, providing a second comparability control alongside the within-subject design. One side of each face was treated and the other left untreated, so that the same skin, of the same age, was assessed over the same period. The product is a cosmetic preparation, evaluated in instrument-graded human studies; every endpoint was machine-read, and sample collection was blinded to the laboratory.
The independent third-party laboratory concluded that the formulation demonstrated firming and anti-wrinkle efficacy at both day 14 and day 28. In the fortnightly cohort, bioelasticity on the treated side had increased by approximately one third by day 28, while the untreated side was essentially unchanged; in the monthly cohort, the treated side gained almost as much while the untreated side declined. Wrinkle depth declined across all five measured zones — forehead, crow's feet, nasolabial, marionette, and neck — while the untreated side of the same face moved in the opposite direction in most zones. The largest improvements were recorded in wrinkle length: crow's-foot length declined by approximately half and forehead-line length by nearly two thirds on the treated side.
The trajectory is as informative as the endpoint. Signals strengthened between day 14 and day 28, increasing in both breadth and magnitude, including in the cohort that had received a single application; this is the opposite of the profile of a fading stimulus, and consolidation rather than rebound is expected with each cell-renewal cycle. Self-assessment agreement ran at 95 to 100 percent across eleven questions at both timepoints, with subjects reporting fuller and more elastic skin, improved laxity, and reduced wrinkles in every zone; every item was significantly above the 60 percent expectation. No adverse reactions were reported in either cohort.
Bioelasticity is the skin's capacity to rebound, measured here by suction-based instrumentation; higher values indicate more youthful behavior. The fortnightly cohort is shown; the monthly cohort reproduces the same direction.
Points to the left of the zero line indicate improvement. Every treated zone improved, while the untreated side of the same face moved in the opposite direction in most zones. Dot positions are proportional to the Cohort A values, which are given in the text. The second cohort reproduces the same direction.
Filled dots indicate endpoints judged significantly superior to the untreated side at day 28: 18 of 21 in Cohort A and 17 of 21 in Cohort B; at day 14, 9 of 21 in each cohort. Dot order is illustrative.
Conventional medical aesthetics addresses the appearance first and defers the cost to the tissue. This product line is constructed in the opposite order: the cells become biologically younger, and the appearance follows.
Energy devices and peels act by wounding the skin and directing the inflammation that follows. The readouts for this product line were obtained with zero adverse reactions among 84 completers; no injury is induced.
The mechanism releases arrested cells, and in platform studies inflammatory signaling declines as senescence recedes; inflammation is therefore not the driver of the effect. In the human cohorts, zero adverse reactions were reported among 84 completers.
Rebuilt collagen self-assembles into the woven network of young skin rather than the parallel-bundle repair collagen that repeated stimulation deposits.
No foreign material is deposited, and none is therefore resorbed. Improvement follows the cell-renewal cycle, and the trajectory from day 14 to day 28 strengthened rather than declined.
Topical skincare hydrates and protects the surface but cannot reach arrested dermal cells. Depth of delivery is the distinguishing factor, and it is a function of the formulation's design.
One approach sustains a younger appearance only while it is repeated. This product line restores younger skin.
The same active agent and the same endpoint system, applied by two pathways for two different uses.
| Regimen A · Skin-quality management | Regimen B · Professional treatment | |
|---|---|---|
| Delivery | Nanocrystal-assisted application, low-trauma | Microneedle roller, professional |
| Cadence | Once every two weeks in the study (two applications) | Once monthly in the study (single application) |
| Character | Repeat-use skin-quality product line | Single strong-delivery course |
| Bioelasticity, day 28 | +34.25% | +30.45% |
| Nasolabial depth, day 28 | −18.30% | −16.12% |
| Day-28 significant endpoints | 18 / 21 | 17 / 21 |
Two independent cohorts; not a randomized head-to-head comparison. Values are treated side versus baseline at day 28.
Freeze-dried powder plus solvent, stable through ambient distribution, reconstituted at the point of use.
Applied topically with device assistance, by nanocrystal or microneedle, placing the active agent at the depth at which the mechanism operates.
Registration completed; commercial rollout underway across multiple channels.